"These study results are encouraging, as they provide additional evidence that FORTEO treatment may result in increased bone strength in appropriate patients," said Kelly Krohn, MD, Eli Lilly and Company. "Studies that reinforce the already established efficacy of medications can help healthcare professionals determine the right medicine to treat their patients with osteoporosis."
FORTEO is used in both men and postmenopausal women with osteoporosis who are at high risk for having broken bones (fractures). FORTEO is used in both men and women with osteoporosis due to use of glucocorticoid medicines, such as prednisone, for several months, who are at high risk for having broken bones (fractures). FORTEO can be used by people who have had a fracture related to osteoporosis, or who have several risk factors for fracture, or who cannot use other osteoporosis treatments.5
FORTEO is a prescription medicine given as a 20 mcg once daily dose available in a 2.4 mL prefilled delivery device for subcutaneous injection over 28 days.5
During the drug testing process, the medicine in FORTEO caused some rats to develop osteosarcoma, which, in humans, is a serious but rare bone cancer. Osteosarcoma has been reported rarely in people who took FORTEO, and it is unknown if people who take FORTEO have a higher chance of getting the disease. Before patients take FORTEO, patients should tell their healthcare provider if they have Paget's disease of bone, are a child or young adult whose bones are still growing or have had radiation therapy.5 For more information about FORTEO, please see the important s
|SOURCE Eli Lilly and Company|
Copyright©2010 PR Newswire.
All rights reserved